The blood-based test is intended to aid in the decision for prostate biopsy for men older than 50 with elevated PSA levels.

Of the 30 companies in the index, 25 saw their share prices increase and four saw their stock prices decline, while one company was flat month over month.

Last week, readers were most interested in a story about FDA's plan to reclassify some tests that now require PMAs to require only 510(k) clearance.